Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Short interest in 6855 has climbed sharply over the past month, even as a broad Hong Kong biotech rally lifted peers by double digits, leaving Ascentage Pharma as one of the more distinctly bearish bets in the sector.
The positioning story is the week's central tension. Short interest has grown 41% over the past 30 days to reach 8.8% of the free float, with the weekly pace accelerating to 7.3%. That puts the borrowed position at roughly 32.5 million shares. The borrow market has tightened in tandem: availability has dropped from well above 400% in early September to 174% now, a meaningful compression even if absolute availability remains adequate. Cost to borrow has edged up 11% over the week to 2.6%, not a distressed level, but the trend is consistently higher. The ORTEX short score is 75.7, near its 10-day high, and ranking in the bottom 7th percentile of the universe for short-score positioning. Together these signals point to a deliberate, building short conviction rather than opportunistic hedging.
The stock itself gained nearly 10% on Tuesday and is up 1.4% on the week, but that follows a 12% decline over the prior month. The one-day bounce is the obvious flashpoint: short interest barely moved on Tuesday, down just 0.2%, suggesting shorts held their ground rather than covering into the rally. That is worth watching. Among closest peers, 9926 gained 20% on the week and 6990 added 5%, while Ascentage's 1.4% weekly move continues a pattern of underperformance against the peer group that prior ORTEX notes flagged as far back as mid-September.
The analyst picture is thin. The mean price target from available data implies a significant premium to the current HKD 30.78 price, but the most recent analyst input is from late August, more than 40 days old, so that figure carries limited weight as a near-term signal. On factor scores, EPS momentum over both 30 and 90 days ranks in the low single digits, and EPS surprise sits at the 9th percentile, reflecting a company still posting losses with a negative P/E. The dividend score at 72 is a quirk of the scoring system for a pre-profit biotech and carries no practical weight. Valuation multiples are all negative, as expected for a loss-making drug developer, though the EV/EBITDA figure has become less negative over 30 days as losses narrow.
The ownership register adds context to the short build. Takeda Pharmaceutical holds 6.6% with no recent change, while chairman and CEO Dajun Yang holds 6.3% and added a small number of shares via option exercise in May. The most recent insider activity on record is those May exercises, with a significance score of just 1, making them a compensation mechanic rather than a signal. Institutional coverage is modest, with 39 holders in total. BlackRock added 65,200 shares through the end of September, and Norges Bank added 335,000 through June, both small moves but in the same direction as the stock's longer-term supporters.
The next earnings event is scheduled for 19 November. The two most recent post-result sessions both produced day-one declines of roughly 4% to 5%, with mixed five-day follow-through. With the short position building into that date, the gap between accumulated bearish positioning and any positive newsflow from the company's oncology pipeline is the dynamic most worth tracking between now and mid-November.
See the live data behind this article on ORTEX.
Open 6855 on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
